Source published November 16, 2026: UTHealth Houston announcement that its site is recruiting for RESONATE, checked against ClinicalTrials.gov NCT07594483 and the sponsor's current trial page.
A safety-first early study UTHealth Houston has opened recruitment for RESONATE, a multicenter early-feasibility study of the investigational Motif eXternally powered Cortical Stimulation System for adults with treatment-resistant depression. The national study plans to enroll 20 people. No participant results are available.
The study is single-arm and open-label. Everyone enrolled receives the investigational system, so there is no sham or randomized comparison. Its primary purpose is to characterize device- and procedure-related adverse events over 12 months. Researchers will also track tolerability, depressive symptoms, anxiety, quality of life and memory. Those secondary measures may help plan later trials, but they cannot by themselves establish comparative effectiveness.
What makes the approach different The source describes a small programmable contact placed within an opening in the skull over the left dorsolateral prefrontal cortex. It rests outside the dura rather than entering brain tissue. An external wearable supplies power and communicates with the implanted component during treatment. This is not the same as noninvasive TMS and not the same as conventional deep brain stimulation.
The system is investigational. Its safety and effectiveness for depression have not been established. Participation includes surgery, healing, clinic-based stimulation and follow-up, with potential risks related to the procedure, infection, stimulation and the implanted component.
Why recruitment is news, not a result Opening another academic site expands access to a tightly supervised first-in-human development program and is a meaningful step in evaluating the technology. It does not show that the implant works, that home use will be safe, or that it improves on TMS, medication, psychotherapy, electroconvulsive therapy or other established options.
A 20-person uncontrolled study is designed to identify feasibility and safety signals, not provide definitive benefit estimates. Future reporting will need participant flow, device and procedure events, stimulation-related effects, withdrawals, protocol adherence, complete symptom estimates with uncertainty and longer-term follow-up.
For prospective participants The institutional page lists detailed eligibility criteria and emphasizes voluntary informed consent. An inquiry does not establish eligibility or obligate anyone to participate. People considering the study should discuss the surgical burden, alternatives, potential benefits, known and unknown risks, travel and follow-up requirements with the research team and their treating clinicians.
Disclosure This is coverage of an institutional trial-recruitment announcement, not a treatment recommendation or efficacy report. Motif Neurotech sponsors RESONATE. Prepared with AI assistance; the UTHealth Houston announcement, current registry record and sponsor trial page were checked November 20, 2026. The image is an AI-generated conceptual illustration. It does not depict the actual implant, wearable, anatomy, surgery, measured data or a clinical outcome.
